CME Group (NASDAQ:CME) Stock: Insider John Clifford Marchese Sells 655 Shares

CME Group logo with Finance background
Image from MarketBeat Media, LLC.

Key Points

  • CME Group General Counsel John Clifford Marchese sold 655 shares for about $203,541, reducing his stake by 18.2% to 2,943 shares.
  • Quarterly results topped expectations: earnings were $3.02 per share versus $2.99 forecast, while revenue rose 10.6% year over year to $1.74 billion.
  • The company declared a quarterly dividend of $1.30 per share, equivalent to $5.20 annualized and a 1.7% yield.
  • MarketBeat previews top five stocks to own in December.

CME Group Inc. (NASDAQ:CME - Get Free Report) General Counsel John Clifford Marchese sold 655 shares of the business's stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $310.75, for a total transaction of $203,541.25. Following the sale, the general counsel owned 2,943 shares in the company, valued at $914,537.25. This trade represents a 18.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

CME Group Stock Down 1.3%

Shares of CME traded down $3.94 during mid-day trading on Thursday, hitting $306.31. 2,451,943 shares of the company's stock were exchanged, compared to its average volume of 2,467,037. The stock's 50-day moving average is $288.15 and its 200-day moving average is $281.93. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.02 and a current ratio of 1.02. CME Group Inc. has a fifty-two week low of $218.31 and a fifty-two week high of $329.16. The company has a market cap of $109.64 billion, a price-to-earnings ratio of 25.13, a P/E/G ratio of 3.80 and a beta of 0.15.

CME Group (NASDAQ:CME - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The financial services provider reported $3.02 earnings per share for the quarter, beating analysts' consensus estimates of $2.99 by $0.03. CME Group had a net margin of 63.33% and a return on equity of 16.23%. The firm had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.71 billion. During the same quarter in the previous year, the business posted $2.68 earnings per share. The business's quarterly revenue was up 10.6% compared to the same quarter last year. On average, sell-side analysts anticipate that CME Group Inc. will post 12.35 earnings per share for the current fiscal year.

CME Group Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Friday, December 11th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Friday, December 11th. CME Group's dividend payout ratio (DPR) is currently 42.66%.

Institutional Trading of CME Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in CME Group in the second quarter valued at $6,749,965,000. Bank of New York Mellon Corp purchased a new position in shares of CME Group during the second quarter worth about $867,313,000. Alphabet Inc. acquired a new stake in shares of CME Group during the second quarter worth about $769,376,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of CME Group during the second quarter worth about $629,771,000. Finally, Bank of America Corp DE acquired a new stake in shares of CME Group during the second quarter worth about $622,679,000. Institutional investors and hedge funds own 87.75% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CME shares. Barclays upped their price objective on CME Group from $281.00 to $321.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 22nd. Wells Fargo & Company boosted their target price on CME Group from $315.00 to $333.00 and gave the stock an "overweight" rating in a research note on Thursday, October 22nd. JPMorgan Chase & Co. upgraded CME Group from an "underweight" rating to an "overweight" rating and set a $367.00 price target on the stock in a report on Thursday, October 22nd. Weiss Ratings raised CME Group from a "buy (b)" rating to a "buy (b+)" rating in a research report on Friday, November 13th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $330.00 price objective (up from $295.00) on shares of CME Group in a research note on Thursday, October 22nd. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $314.44.

Read Our Latest Research Report on CME Group

About CME Group

(Get Free Report)

CME Group operates a global marketplace for derivatives and other financial products. Through its exchanges—CME, CBOT, NYMEX and COMEX—it offers futures and options contracts tied to interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The company also provides clearing and settlement services, market data and related products. Its electronic trading platform, CME Globex, supports access to its markets by participants around the world, alongside its open-outcry and privately negotiated trading services.

Read More

Insider Buying and Selling by Quarter for CME Group (NASDAQ:CME)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CME Group Right Now?

Before you consider CME Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.

While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines